Frontlight ResearchEarly access
Not yet taking people in AustriaPhase 1
Tests NTR-641 in healthy adults and people with acute ischemic stroke
Tests NTR-641 for safety in healthy adults and adults with acute ischemic stroke.
Key facts
- Who runs it
- Neutrolis Inc.
- Where
- Vienna, AustriaSee the 2 sites
- Trial code
- Registry title
- A randomized, placebo-controlled, double-blind, single-ascending-dose, Phase 1a/b study to assess the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of intravenous NTR-641 in healthy adults and patients with acute ischemic stroke
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 72 people, planned
- Started
- 14 Oct 2024
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional
- Record updated
- 21 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy adults and adults with acute ischemic stroke to test the safety of a drug called NTR-641 given into a vein.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Acute ischemic stroke (for the patient part); healthy adults are also included
Where in Austria
- Krankenhaus Der Barmherzigen Brueder WienVienna, AustriaNot yet recruiting
- Medical University of ViennaVienna, AustriaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Tests NTR-641 in healthy adults and people with acute ischemic strokeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 21 July 2025